+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Breast Cancer Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Breast Cancer Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5206469
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Breast Cancer Diagnostics Market is projected to reach USD 7.24 Billion in 2026. It is expected to continue growing at a CAGR of 8.03%, reaching USD 11.54 Billion by 2032.

Breast cancer diagnostics is moving from episodic detection toward integrated, risk-based care that combines screening mammography, ultrasound, MRI, biopsy, histopathology, immunohistochemistry, genomic assays, and digital pathology. The clinical urgency is clear: the World Health Organization reported about 2.3 million women diagnosed with breast cancer and roughly 670,000 deaths worldwide in 2022, making timely detection and accurate diagnosis central to cancer control.

For industry leaders, opportunity is tied to earlier detection, faster confirmation, and more precise treatment selection. Demand is strongest where organized screening, reimbursement, pathology capacity, and oncology infrastructure align, making diagnostic accuracy, workflow efficiency, access expansion, and evidence-based care pathways central competitive differentiators.

Transformative Shifts in Breast Cancer Diagnostics

The landscape is being reshaped by three structural shifts: expanded screening access, precision oncology, and digitally enabled diagnostics. Digital breast tomosynthesis is improving lesion visualization, while MRI and ultrasound remain important for dense breast tissue, high-risk patients, and diagnostic follow-up. Updated screening guidance in several countries is also strengthening attention on risk stratification, breast density, and timely diagnostic workup after abnormal findings.

At the same time, biomarker testing for ER, PR, HER2, Ki-67, and multigene recurrence risk has made diagnostics essential to therapy selection. Laboratories and imaging providers are investing in interoperability, quality assurance, standardized reporting, and faster turnaround as health systems prioritize earlier-stage detection, multidisciplinary decision-making, and patient-centered care pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a measurable force in breast imaging and pathology workflows. FDA-listed AI/ML-enabled medical devices are concentrated heavily in radiology, and breast imaging tools are increasingly used for detection support, triage, breast density assessment, image quality review, and quality control. In pathology, AI-assisted image analysis is gaining relevance for digital slide review, workflow prioritization, and reproducibility support.

Evidence is advancing. The MASAI randomized screening trial reported that AI-supported mammography detected more cancers while reducing screen-reading workload, supporting the case for AI as an assistive technology rather than a standalone replacement for radiologists. Adoption will depend on clinical validation, bias monitoring across population groups, cybersecurity, reimbursement, and integration with PACS, RIS, laboratory information systems, and electronic health records.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia increase screening participation, diagnostic imaging capacity, and oncology infrastructure. Growth is supported by rising awareness, expanding private healthcare, and government-led cancer control initiatives, although rural access, affordability, and pathology workforce gaps remain significant in parts of the region. Japan, South Korea, and Australia have mature imaging systems, while China and India continue to scale mammography, ultrasound, biopsy, and pathology services for large populations.

North America leads in advanced mammography, molecular diagnostics, image-guided biopsy, and AI-enabled workflows, supported by reimbursement, clinical guidelines, cancer registries, and strong cancer center networks. Europe benefits from organized screening programs, quality assurance standards, and broad adoption of pathology and biomarker testing across many health systems. Latin America shows rising demand for breast imaging and confirmatory diagnostics, but access remains uneven between urban centers and underserved regions. The Middle East is investing in specialty hospitals, screening campaigns, and imaging networks, whereas Africa faces late-stage presentation, limited mammography density, and pathology bottlenecks that make scalable, cost-effective diagnostics essential.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are characterized by rising cancer awareness, expanding urban diagnostic centers, and uneven public screening coverage, creating demand for affordable mammography, ultrasound, biopsy, and pathology services. GCC countries are investing in modern oncology ecosystems, digital hospitals, and national screening initiatives, making premium imaging, integrated diagnostics, and AI-supported workflows increasingly attractive in tertiary care settings.

The European Union benefits from coordinated cancer policy, population-based screening recommendations, conformity assessment standards, and cross-border evidence generation. BRICS markets combine large patient populations with expanding healthcare infrastructure, making access, price-performance, training, and localized service models important for adoption. G7 countries lead in reimbursement depth, guideline-based screening, digital pathology readiness, AI evaluation, and precision diagnostics. NATO member markets add resilience, cybersecurity, data governance, and supply continuity considerations to procurement decisions for critical diagnostic technologies.

Key Country Insights in Breast Cancer Diagnostics

The United States remains a major innovation and adoption hub, with the American Cancer Society estimating more than 310,000 new invasive breast cancer cases in women in 2024 and strong use of mammography, biopsy, pathology, immunohistochemistry, genomic testing, and AI-enabled imaging tools. Canada emphasizes organized screening and equitable provincial access, while Mexico and Brazil show growing demand for diagnostic imaging and pathology services but continue to face regional disparities in screening participation, diagnostic turnaround, and access to specialty oncology care.

The United Kingdom, Germany, France, Italy, and Spain rely on established screening and pathology systems, supported by national or regional breast screening programs, multidisciplinary cancer care, and broad biomarker testing. Russia maintains demand for imaging modernization and oncology infrastructure development. China and India represent scale-driven growth as awareness, hospital investment, and cancer programs expand, while access gaps persist between major cities and lower-resource settings. Japan and South Korea emphasize high-quality imaging, health checkup culture, and technology adoption, and Australia benefits from organized screening, strong clinical governance, and established breast cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that shorten the time from abnormal screen to confirmed diagnosis. Investment should focus on interoperable imaging, biopsy guidance, pathology digitization, biomarker testing, and AI tools that demonstrate measurable gains in detection accuracy, workflow efficiency, reproducibility, or patient outcomes.

Commercial strategies must align with local reimbursement, screening policy, regulatory expectations, data governance, and workforce realities. Vendors should build evidence packages for regulators and payers, support training for radiologists, pathologists, technologists, and laboratory teams, and develop tiered offerings for high-income, emerging, and resource-constrained markets without compromising quality assurance or patient safety.

Research Methodology

This research applies a triangulated methodology using verified secondary sources, primary expert inputs, and analytical validation. Core references include WHO, IARC/GLOBOCAN, national cancer registries, CDC, American Cancer Society, USPSTF, FDA device databases, OECD health data, professional society guidelines, and public reimbursement, procurement, and regulatory information.

The research process evaluates epidemiology, screening policy, technology adoption, regulatory pathways, payer dynamics, clinical workflow, competitive positioning, and regional healthcare infrastructure. Findings are cross-checked to avoid unsupported projections and to ensure that market interpretation remains grounded in documented clinical, regulatory, and healthcare system evidence.

Conclusion

Breast cancer diagnostics is entering a new phase defined by earlier detection, precision biomarker testing, digital workflow integration, and responsible AI adoption. The strongest opportunities will emerge where technologies improve diagnostic confidence, reduce delays, and connect imaging with pathology, molecular testing, and treatment planning.

As disease burden remains high worldwide, stakeholders that combine clinical evidence, access strategy, regulatory readiness, data security, and scalable implementation will be best positioned to lead in breast cancer diagnostics while supporting better outcomes across diverse healthcare settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Breast Cancer Diagnostics Market, by Offering
7.1. Introduction
7.2. Instruments
7.2.1. Biopsy Devices
7.2.2. Imaging Systems
7.2.3. Sequencers
7.3. Consumables & Reagents
7.3.1. Assay Kits
7.3.2. Slides & Staining Reagents
7.4. Software
7.4.1. Workflow Informatics
7.4.2. Data Analysis Software
7.5. Services
7.5.1. Consulting
7.5.2. Installation & Maintenance
8. Breast Cancer Diagnostics Market, by Technology
8.1. Introduction
8.2. Biopsy
8.2.1. Needle Biopsy
8.2.2. Surgical Biopsy
8.3. Histopathology
8.3.1. Immunohistochemistry
8.3.2. Routine Histology
8.4. Imaging
8.4.1. Mammography
8.4.2. Magnetic Resonance Imaging (MRI)
8.4.3. Ultrasound
8.5. Molecular Diagnostics
8.5.1. Fluorescence In Situ Hybridization (FISH)
8.5.2. Next-Generation Sequencing (NGS)
8.5.3. PCR-Based
9. Breast Cancer Diagnostics Market, by Biomarker Type
9.1. Introduction
9.2. BRCA
9.3. ER/PR
9.4. HER2
9.5. Ki-67
10. Breast Cancer Diagnostics Market, by Sample Type
10.1. Introduction
10.2. Blood
10.3. Serum
10.4. Tissue
11. Breast Cancer Diagnostics Market, by Clinical Use Case
11.1. Introduction
11.2. Population Screening
11.3. Diagnostic Confirmation
11.4. Risk Stratification
11.5. Therapy Selection
11.6. Treatment Monitoring
11.7. Recurrence Surveillance
12. Breast Cancer Diagnostics Market, by End User
12.1. Introduction
12.2. Cancer Research Centers
12.3. Diagnostic Laboratories
12.4. Hospitals & Clinics
13. Breast Cancer Diagnostics Market, by Region
13.1. Introduction
13.2. North America
13.3. Asia-Pacific
13.4. Europe
13.5. Latin America
13.6. Middle East
13.7. Africa
14. Breast Cancer Diagnostics Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. European Union
14.5. BRICS
14.6. ASEAN
14.7. GCC
15. Breast Cancer Diagnostics Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. Japan
15.6. Canada
15.7. United Kingdom
15.8. India
15.9. France
15.10. South Korea
15.11. Mexico
15.12. Italy
15.13. Australia
15.14. Brazil
15.15. Russia
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Hologic, Inc.
17.2. F. Hoffmann-La Roche Ltd.
17.3. GE HealthCare Technologies Inc.
17.4. Siemens Healthineers AG
17.5. Thermo Fisher Scientific Inc.
17.6. Koninklijke Philips N.V.
17.7. FUJIFILM Holdings Corporation
17.8. Bio-Rad Laboratories, Inc.
17.9. Illumina, Inc.
17.10. Danaher Corporation
17.11. Abbott Laboratories
17.12. Becton, Dickinson and Company
17.13. Agilent Technologies, Inc.
17.14. Cardinal Health, Inc.
17.15. 4D Path Inc.
17.16. AstraZeneca PLC
17.17. Biodesix, Inc.
17.18. Exact Sciences Corporation
17.19. Fluxion Biosciences Inc. by Cell Microsystems
17.20. NanoString Technologies, Inc.
17.21. NeoGenomics Laboratories
17.22. Olea Medical
17.23. OncoGenomX
17.24. Planmed Oy
17.25. Quest Diagnostics Incorporated
17.26. Todos Medical Ltd.
17.27. TransMed7, LLC
18. Key Experts
List of Figures
FIGURE 1. Global Breast Cancer Diagnostics Market, Years Considered for the Study
FIGURE 2. Global Breast Cancer Diagnostics Market, Research Design
FIGURE 3. Global Breast Cancer Diagnostics Market, Research Framework
FIGURE 4. Global Breast Cancer Diagnostics Market, Data Triangulation
FIGURE 5. Global Breast Cancer Diagnostics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Breast Cancer Diagnostics Market Size, by Offering, 2025 vs 2032 (%)
FIGURE 7. Global Breast Cancer Diagnostics Market Size, by Offering, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Breast Cancer Diagnostics Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Breast Cancer Diagnostics Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Breast Cancer Diagnostics Market Size, by Biomarker Type, 2025 vs 2032 (%)
FIGURE 11. Global Breast Cancer Diagnostics Market Size, by Biomarker Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Breast Cancer Diagnostics Market Size, by Sample Type, 2025 vs 2032 (%)
FIGURE 13. Global Breast Cancer Diagnostics Market Size, by Sample Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2025 vs 2032 (%)
FIGURE 15. Global Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Breast Cancer Diagnostics Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Breast Cancer Diagnostics Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Breast Cancer Diagnostics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Breast Cancer Diagnostics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Breast Cancer Diagnostics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Breast Cancer Diagnostics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Breast Cancer Diagnostics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Breast Cancer Diagnostics Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Breast Cancer Diagnostics Market Segmentation & Coverage
TABLE 2. Global Breast Cancer Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 3. Global Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 4. Global Instruments Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Instruments Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Instruments Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Biopsy Devices Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Biopsy Devices Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Biopsy Devices Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Imaging Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Imaging Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Imaging Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Sequencers Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Sequencers Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Sequencers Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Consumables & Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Consumables & Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Consumables & Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Assay Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Assay Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Assay Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Slides & Staining Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Slides & Staining Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Slides & Staining Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Workflow Informatics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Workflow Informatics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Workflow Informatics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Data Analysis Software Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Data Analysis Software Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Data Analysis Software Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Consulting Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Consulting Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Consulting Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Installation & Maintenance Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Installation & Maintenance Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Installation & Maintenance Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 44. Global Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Biopsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Biopsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Needle Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Needle Biopsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Needle Biopsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Surgical Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Surgical Biopsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Surgical Biopsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Histopathology Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Histopathology Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Histopathology Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Immunohistochemistry Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Immunohistochemistry Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Immunohistochemistry Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Routine Histology Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Routine Histology Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Routine Histology Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Mammography Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Mammography Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Mammography Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Magnetic Resonance Imaging (MRI) Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Magnetic Resonance Imaging (MRI) Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Magnetic Resonance Imaging (MRI) Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Ultrasound Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Ultrasound Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Ultrasound Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Molecular Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Molecular Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Molecular Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Fluorescence In Situ Hybridization (FISH) Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Fluorescence In Situ Hybridization (FISH) Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Fluorescence In Situ Hybridization (FISH) Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Next-Generation Sequencing (NGS) Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Next-Generation Sequencing (NGS) Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Next-Generation Sequencing (NGS) Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global PCR-Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global PCR-Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global PCR-Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 87. Global BRCA Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global BRCA Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global BRCA Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global ER/PR Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global ER/PR Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global ER/PR Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global HER2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global HER2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global HER2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Ki-67 Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Ki-67 Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Ki-67 Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 100. Global Blood Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Blood Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Blood Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Serum Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Serum Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Serum Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Tissue Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Tissue Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Tissue Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 110. Global Population Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Population Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Population Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Diagnostic Confirmation Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Diagnostic Confirmation Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Diagnostic Confirmation Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Risk Stratification Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Risk Stratification Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Risk Stratification Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Therapy Selection Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Therapy Selection Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Therapy Selection Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Treatment Monitoring Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Treatment Monitoring Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Treatment Monitoring Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Recurrence Surveillance Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Recurrence Surveillance Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Recurrence Surveillance Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Global Cancer Research Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Global Cancer Research Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. Global Cancer Research Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 132. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. North America Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 140. North America Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 141. North America Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 142. North America Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 143. North America Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 144. North America Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 145. North America Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 146. North America Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 147. North America Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 148. North America Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 149. North America Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 150. North America Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 151. North America Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 152. North America Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 153. North America Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Europe Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Europe Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 171. Europe Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 172. Europe Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 173. Europe Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 174. Europe Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 175. Europe Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 176. Europe Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 177. Europe Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 178. Europe Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 179. Europe Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 180. Europe Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 181. Europe Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 182. Europe Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 183. Europe Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Latin America Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 185. Latin America Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 186. Latin America Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 187. Latin America Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 188. Latin America Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 189. Latin America Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 190. Latin America Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 191. Latin America Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 192. Latin America Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 193. Latin America Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 194. Latin America Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 195. Latin America Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 196. Latin America Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 197. Latin America Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 198. Latin America Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Middle East Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Middle East Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 201. Middle East Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 202. Middle East Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 203. Middle East Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 204. Middle East Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 205. Middle East Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 206. Middle East Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 207. Middle East Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 208. Middle East Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 209. Middle East Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 210. Middle East Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 211. Middle East Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 212. Middle East Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 213. Middle East Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. Africa Breast Cancer Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. Africa Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 216. Africa Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 217. Africa Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 218. Africa Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 219. Africa Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 220. Africa Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 221. Africa Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 222. Africa Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 223. Africa Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 224. Africa Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 225. Africa Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 226. Africa Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 227. Africa Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 228. Africa Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. Global Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. NATO Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. NATO Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 232. NATO Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 233. NATO Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 234. NATO Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 235. NATO Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 236. NATO Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 237. NATO Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 238. NATO Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 239. NATO Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 240. NATO Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 241. NATO Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 242. NATO Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 243. NATO Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 244. NATO Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. G7 Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. G7 Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 247. G7 Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 248. G7 Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 249. G7 Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 250. G7 Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 251. G7 Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 252. G7 Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 253. G7 Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 254. G7 Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 255. G7 Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 256. G7 Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 257. G7 Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 258. G7 Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 259. G7 Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. European Union Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 261. European Union Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 262. European Union Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 263. European Union Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 264. European Union Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 265. European Union Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 266. European Union Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 267. European Union Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 268. European Union Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 269. European Union Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 270. European Union Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 271. European Union Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 272. European Union Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 273. European Union Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 274. European Union Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. BRICS Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 276. BRICS Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 277. BRICS Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 278. BRICS Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 279. BRICS Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 280. BRICS Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 281. BRICS Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 282. BRICS Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 283. BRICS Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 284. BRICS Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 285. BRICS Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 286. BRICS Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 287. BRICS Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 288. BRICS Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 289. BRICS Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 290. ASEAN Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 291. ASEAN Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 292. ASEAN Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 293. ASEAN Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 294. ASEAN Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 295. ASEAN Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 296. ASEAN Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 297. ASEAN Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 298. ASEAN Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 299. ASEAN Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 300. ASEAN Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 301. ASEAN Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 302. ASEAN Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 303. ASEAN Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 304. ASEAN Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 305. GCC Breast Cancer Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 306. GCC Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 307. GCC Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 308. GCC Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 309. GCC Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 310. GCC Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 311. GCC Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 312. GCC Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 313. GCC Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 314. GCC Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 315. GCC Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 316. GCC Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 317. GCC Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 318. GCC Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 319. GCC Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. Global Breast Cancer Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 321. United States Breast Cancer Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 322. United States Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 323. United States Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 324. United States Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 325. United States Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 326. United States Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 327. United States Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 328. United States Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 329. United States Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 330. United States Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 331. United States Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 332. United States Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 333. United States Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 334. United States Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 335. United States Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 336. China Breast Cancer Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 337. China Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 338. China Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 339. China Breast Cancer Diagnostics Market Size, by Consumables & Reagents, 2017-2032 (USD Million)
TABLE 340. China Breast Cancer Diagnostics Market Size, by Software, 2017-2032 (USD Million)
TABLE 341. China Breast Cancer Diagnostics Market Size, by Services, 2017-2032 (USD Million)
TABLE 342. China Breast Cancer Diagnostics Market Size, by Technology, 2017-2032 (USD Million)
TABLE 343. China Breast Cancer Diagnostics Market Size, by Biopsy, 2017-2032 (USD Million)
TABLE 344. China Breast Cancer Diagnostics Market Size, by Histopathology, 2017-2032 (USD Million)
TABLE 345. China Breast Cancer Diagnostics Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 346. China Breast Cancer Diagnostics Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 347. China Breast Cancer Diagnostics Market Size, by Biomarker Type, 2017-2032 (USD Million)
TABLE 348. China Breast Cancer Diagnostics Market Size, by Sample Type, 2017-2032 (USD Million)
TABLE 349. China Breast Cancer Diagnostics Market Size, by Clinical Use Case, 2017-2032 (USD Million)
TABLE 350. China Breast Cancer Diagnostics Market Size, by End User, 2017-2032 (USD Million)
TABLE 351. Germany Breast Cancer Diagnostics Market Size, 2017-2032 (USD Million)
TABLE 352. Germany Breast Cancer Diagnostics Market Size, by Offering, 2017-2032 (USD Million)
TABLE 353. Germany Breast Cancer Diagnostics Market Size, by Instruments, 2017-2032 (USD Million)
TABLE 354. Germany Breast Cancer Diagnostics Market Size, by Consumables & Reage

Companies Mentioned

  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Koninklijke Philips N.V.
  • FUJIFILM Holdings Corporation
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Agilent Technologies, Inc.
  • Cardinal Health, Inc.
  • 4D Path Inc.
  • AstraZeneca PLC
  • Biodesix, Inc.
  • Exact Sciences Corporation
  • Fluxion Biosciences Inc. by Cell Microsystems
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Planmed Oy
  • Quest Diagnostics Incorporated
  • Todos Medical Ltd.
  • TransMed7, LLC

Table Information

Report AttributeDetails
No. of Pages185
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.54 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Breast Cancer Diagnostics - Global Strategic Business Report - Product Image

Breast Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 467 Pages
  • Global
From
Breast Cancer Core Needle Biopsy - Global Strategic Business Report - Product Image

Breast Cancer Core Needle Biopsy - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2026-2034 - Product Image

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2026-2034

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.